Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board
21. März 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is honored to...
Dr. Gerard Blobe, M.D., Ph.D., Joins Vivacitas Oncology's Solid Tumor Medical Advisory Board
07. März 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, proudly announces that Dr. Gerard Blobe, M.D.,...
Vivacitas Oncology to Present at the 2022 BIO CEO & Investor Conference
14. Februar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, will present at the upcoming 2022 BIO...
Dr. Volker W. Stieber, MD, Joins Vivacitas' Neuro-Oncology Advisory Board
07. Februar 2022 10:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, is proud to present Dr. Volker W....
Vivacitas Oncology Strengthens Its Neuro-Oncology Board With World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN
31. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, continues to grow its Neuro-Oncology...
Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit
18. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will be attending and presenting a poster on...
Dr. Erkut Borazanci, MD, Joins Vivacitas Oncology's Pancreatic Medical Advisory Board
17. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, proudly announces that Dr. Erkut Borazanci, MD,...
Vivacitas Oncology to Present AR-67 at the Biotech Showcase Investor Conference
10. Januar 2022 11:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately held clinical stage biopharmaceutical company focused on tough-to-treat...
Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board
03. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately held oncology company focused on tough-to-treat cancers, is pleased to...
Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN
15. Dezember 2021 15:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is pleased to...